Skip to main content
×
×
Home

Pharmacogenomic perspectives on the management of mood disorders

  • Renato D. Alarcón (a1)
Summary

Psychiatric pharmacogenomics is a relatively young field of clinical practice, focused on the identification of genetic profiles determining varieties of metabolic patterns that, in turn, assist in the choice of appropriate medications and their corresponding doses. In psychiatry, the mood disorders area has been the most active in trying to advance knowledge and expertise in pharmacogenomics. the cytochrome P450 system (particularly 2D6 and 2C19 enzymes and their respective codifying genes) and, more recently, serotonin transporter and receptor gene tests are among the most utilised and promising. In spite of encouraging findings, however, there are still many questions related to preciseness, scope, ethnic variations, diagnostic implications, ‘non-biological’ factors, and ethic considerations. the need of algorithms, follow-up studies, and assessment of financial impact, all listed here, require continuous and systematic research. It will not only add to the excitement of pharmacogenomics, but also to the creation of cogent evidence of its benefits.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacogenomic perspectives on the management of mood disorders
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pharmacogenomic perspectives on the management of mood disorders
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pharmacogenomic perspectives on the management of mood disorders
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
1 Charney, DS, Nestler, EJ. Neurobiology of Mental Illness (3rd ed). Oxford University Press, 2009.
2 LaPorte, JL, Ren-Patterson, RF, Murphy, DL, Kalueff, AV. Refining psychiatric genetics: from ‘mouse psychiatry’ to understanding complex human disorders. Behav Pharmacol 2008; 19: 377–84.
3 Mrazek, DA. Current application of clinical genetic testing for psychiatric practice. Minn Med 2007; 90: 42–3.
4 Bertilsson, L, Dahl, ML, Tybring, G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 1997; 391 (suppl): 1421.
5 Weinshilboum, R. Inheritance and drug response. New Engl J Med 2003; 348: 529–37.
6 Ingelman-Sundberg, M. Human drug metabolizing cythochrome P450 enzymes: properties and polymorphisms. Arch Psychopharmacol 2004; 369:89104.
7 Black, JL, O'Kane, DJ, Mrazek, DA. The impact of CYP allelic variations on antidepressant metabolism: a review. Expert Opin Drug Metab Toxicol 2007; 3: 21–3.
8 Kirchheiner, J, Bauer, S, Menoke, I, Rohde, W, Prang, V, Meisel, C, et al. CYP 2D6 and CYP2 C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173–92.
9 McMahon, SJ, Buervenich, S, Charney, D, Lipsky, R, Rush, AJ, Wilson, AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genetics 2006; 78: 804–14.
10 Serretti, A, Kato, M, Kennedy, JL. Pharmacogenetic studies in depression: a proposal for methodological guidelines. Pharmacogenomics J 2008; 8: 90100.
11 Smith, M. Ethnopsychopharmacology. In Cultural Psychiatry for Clinicians: A Handbook for Working with Diverse Patients (ed Lim, R): 271–98. American Psychiatric Press, 2006.
12 Mandelli, M, Marino, E, Pirovano, A, Calati, R, Zanardi, R, Colombo, C, et al. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsycho-pharmacol 2009; 19: 64–7.
13 Psychiatric GWAS Consortium Coordinating Committee. Genomewide association studies: history, rationale and prospects for psychiatric disorders. Am J Psychiatry 2009; 166: 540–56.
14 Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP 2D6): clinical consequences, evolutionary aspects, and functional diversity. Pharmacogenomics J 2005; 5: 613.
15 Kato, M, Zanardi, R, Rossini, D, De Ronchi, D, Okugawa, G, Takekita, Y, et al. 5HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiat Res 2009; 117: 97105.
16 Alarcón, RD, Mrazek, DA. Farmacogenómica osiquiátrica: actualización y perspectivas. In Genética y Farmacogenómica en Psiquiatría (ed Silva, H): 5979. C&C Ediciones SONEPSYN, 2007.
17 Novoa, F. Desafíos éticos en la investigación y aplicación clínica de la genética. In Genética y Farmacogenómica en Psiquiatría (ed Silva, H): 121–37. C&C Ediciones SONEPSYN, 2007.
18 Kirchheiner, J, Seeringer, A. Clinical implications of pharmacogenetics of cytochromc P450 drug metabolizing enzymes. Biochem Biophys Acta 2007; 1770: 489494.
19 Kung, S, Winner, JG, Alarcón, RD, Shinozaki, G, Frye, M, Mrazek, DA, et al. Patients' and clinicians' satisfaction with pharmacogenomic testing for depressed inpatients at the Mayo Clinic Mood Disorders Unit. Poster Presentation, Annual Meeting, American Psychiatric Association, San Francisco, California, 16–21 May 2009.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 5 *
Loading metrics...

Abstract views

Total abstract views: 24 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 21st July 2018. This data will be updated every 24 hours.

Pharmacogenomic perspectives on the management of mood disorders

  • Renato D. Alarcón (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *